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Abstract: CPT-11 is a widely-used anti-cancer drug that is converted in vivo to its active metabolite, SN-38. In the liver, 
enzymes detoxify SN-38 by coupling it to a glucuronidate moiety and this inactive compound (SN-38G) is excreted into 
the gastrointestinal tract. In the intestine, commensal bacteria convert the SN-38G back to the active and toxic SN-38 us-
ing bacterial -glucuronidase enzyme (GUS). This intestinal SN-38 causes debilitating diarrhea that prevents dose-
intensification and efficacy in a significant fraction of patients undergoing CPT-11 treatment for cancer. This CPT-11 
metabolic pathway suggests that small molecule inhibitors of GUS may have utility as novel therapeutics for prevention 
of dose-limiting diarrhea resulting from CPT-11 therapy. To identify chemical inhibitors of GUS activity, we employed 
and validated a high throughput, fluorescence-based biochemical assay and used this assay to screen a compound library. 
Novel inhibitors of GUS were identified with IC50 values ranging from 50 nM to 4.8 M. These compounds may be use-
ful as chemical probes for use in proof-of-concept experiments designed to determine the efficacy of GUS inhibitors in al-
tering the intestinal metabolism of drugs. Our results demonstrate that this high throughput assay can be used to identify 
small molecule inhibitors of GUS.  
Keywords: -glucuronidase, CPT-11, screen, inhibitor. 
INTRODUCTION  
  Camptothecin is a potent anti-cancer compound that was 
originally purified from the tree Camptotheca acuminata and 
whose structure was elucidated in 1966 [1]. It inhibits the 
catalytic cycle of human topoisomerase I, which regulates 
the superhelical tension associated with DNA replication and 
is preferentially active in rapidly proliferating cells [2, 3]. In 
preliminary human studies, camptothecin exhibited signifi-
cant toxicity and poor bioavailability [4]. The camptothecin 
derivatives topotecan and CPT-11 (also called irinotecan) 
have since been discovered to have improved toxicity and 
bioavailability properties and these drugs are now in clinical 
use as anti-cancer therapies [4], although they still generate 
debilitating side effects in cancer patients that limit efficacy. 
CPT-11 is one of the three commonly-used chemotherapeu-
tic agents for colon, lung, and brain cancer and it has also 
been used against refractory forms of leukemia and lym-
phoma [5]. CPT-11 is a prodrug, having a carbamate-linked 
dipiperidino group that significantly increases its solubility 
and bioavailability [4]. This dipiperidino group is removed 
in vivo by carboxylesterases to produce the active metabolite, 
SN-38 [6].  
  The dose-limiting side effect of CPT-11 is severe diar-
rhea generated by its complex activation and metabolism   
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[7, 8]. SN-38, the active metabolite of CPT-11, is glucuroni-
dated in the liver by UDP-glucuronosyltransferase (UGT) 
enzymes [9] resulting in the inactive SN-38G [10], which is 
excreted via the biliary ducts into the gastrointestinal (GI) 
tract. Once in the intestines, SN-38G serves as a substrate for 
bacterial -glucuronidase (GUS) enzymes that are produced 
by bacteria normally inhabiting the intestines. The removal 
of the glucuronide group by GUS generates a carbon source 
for the bacteria and, in the process SN-38G is reactivated 
back to the active and toxic SN-38 [11, 12]. This reactivated 
SN-38, now present in the intestinal lumen, is toxic to the 
intestinal cells resulting in delayed diarrhea that prevents 
dose-intensification and efficacy in a significant fraction of 
patients undergoing CPT-11 treatment for cancer [13, 14].  
  The concept of using antibiotics to reduce GI bacteria 
levels to prevent the regeneration of SN-38 in the intestine 
has been examined [15]. However, the use of antibiotics has 
several disadvantages. Intestinal bacteria function in essen-
tial pathways in carbohydrate metabolism, vitamin produc-
tion, and the processing of bile acids, sterols and xenobiotics 
[16, 17]. Thus, the removal of GI bacteria is not recom-
mended for patients already challenged by cancer and che-
motherapy. In addition, elimination of symbiotic GI flora 
increases the chances of infections by pathogenic bacteria, 
including enterohemorrhagic E. coli and Clostridium difficile 
[18-24].  
  -glucuronidase enzymes hydrolyze glucuronic acid 
sugar moieties from a variety of compounds [25]. The pres-14    Current Chemical Genomics, 2011, Volume 5  Ahmad et al. 
ence of GUS in a wide range of bacteria is exploited to de-
tect bacterial contamination in commonly-used water purity 
tests [26]. Prior to our work, only relatively weak inhibitors 
of -glucuronidases with Ki values ranging from 25 M to 2 
mM have been described [27, 28]. Thus, we have sought to 
identify potent and selective inhibitors of bacterial -
glucuronidases to inhibit the generation of SN-38 in the in-
testines and thus reduce or eliminate the GI toxicity of CPT-
11 treatment without killing the useful bacteria required for 
intestinal health. From the high throughput screen for GUS 
inhibitors that is described in this report, we selected four 
hits for follow-up studies. We have recently published the 
results of these studies [29]. These compounds showed com-
plete selectivity for bacterial GUS verses the homologous 
mammalian enzyme. The compounds demonstrated GUS 
inhibitory activity in living bacteria with IC50 values ranging 
from 18 nM to 1.3 M with no effect on bacterial viability 
even at 100 M. Furthermore, oral administration of one of 
these inhibitors protected mice from CPT-11-induced diar-
rhea.  
  In this report, we describe the development and valida-
tion of the high throughput GUS activity assay that led to the 
discovery of small molecule inhibitors of GUS activity. An 
existing GUS activity assay using the fluorigenic substrate 4-
methylumbelliferyl glucuronide (4MUG) was modified and 
formatted for HTS. In this assay, the non-fluorescent 4MUG 
is hydrolyzed by GUS generating 4-methylumbelliferone, a 
highly fluorescent molecule. This optimized and validated 
assay was then used to screen a chemical library in search of 
inhibitors of GUS.  
MATERIALS AND METHODS  
Reagents  
  All common reagents such as HEPES, Triton X-100, D-
Glucaric acid-1,4-lactone and dimethyl sulfoxide (DMSO) 
were reagent-grade quality obtained from Thermo Fisher 
Scientific (Waltham, MA) or Sigma-Aldrich (St. Louis, 
MO). 4-methylumbelliferyl glucuronide (4MUG) was ob-
tained from Sigma. The solid black 384-well plates (cat# 
3573) for the assay were from Corning Incorporated (Corn-
ing, NY). The Prestwick Chemical Library was obtained 
from Prestwick Chemical Company (Washington DC). Ad-
ditional compounds for screening and IC50 determinations 
were obtained from the Asinex Corporation (Moscow, Rus-
sia). The expression and purification of the GUS enzyme 
from BL21-DE3 E. coli cells carrying an expression plasmid 
containing the full-length E. coli GUS gene has been previ-
ously described [29]. 
GUS Assay 
  The GUS assay was performed by the addition of 0.5 μl 
of compound (or DMSO) to the well of a black 384-well 
plate followed by the addition of 30 μl of diluted GUS en-
zyme (83 pM GUS). The enzyme was diluted into 50 mM 
HEPES, pH 7.4 and 0.017% Triton X-100. After addition of 
enzyme, the reaction was initiated by addition of 20 μl of 
4MUG substrate (312.5 M 4MUG) diluted into 50 mM 
HEPES, pH 7.4. 4MUG stock solutions were made in the 
same buffer. Final buffer in the assembled assay was 50 mM 
HEPES, pH 7.4 and 0.01% Triton X-100. Following the ini-
tiation of the reaction with 4MUG, the plates were incubated 
for 30 minutes at 23ºC followed by the addition of 20 μl of 1 
M sodium carbonate solution to stop the reaction. The GUS, 
4MUG, and stop solutions were delivered to the plate using 
Multidrop
TM liquid handlers (Thermo). The plate was then 
read in the Victor V plate reader. The fluorescence was 
measured using the 355 nm excitation filter and 460 nm 
emission filter (the ubelliferone filter set). Read time was 0.1 
s/well and fluorescence expressed in relative fluorescence 
units (RFU). Error bars for data points represent standard 
deviations. Z’-factor values were derived by the published 
formula with Z’-factors of 0.5 – 1.0 indicating that an assay 
is robust for screening [30]. 
High Throughput Screen 
  For the high throughput screening of the Asinex chemical 
library, 0.5 μl of 1 mM compound in 100% DMSO was 
added to empty 384-well plates using a Biomek NX (Beck-
man Coulter Inc., Fullerton, CA), resulting in a final com-
pound concentration of 10 μM for the primary screen. This 
dry spotting of compounds into assay plates was performed 
as a routine method of conserving compound stock solutions. 
This spotting method has been validated for transfer of 0.5 μl 
DMSO with a CV of 6.3% and 98% accuracy. Final assay 
concentrations in the 50 μl enzyme reaction were 50 pM 
GUS, 125 μM 4MUG, 10 M compound, 1% DMSO (from 
compound). For the screening, each plate had maximum 
(max) and minimum (min) controls with DMSO spotted in 
the wells. Max signal positive control wells contained only 
DMSO (no compound), while the min signal control wells 
were obtained by adding enzyme dilution buffer instead of 
GUS. D-Glucaric acid-1,4-lactone would not dissolve in 
DMSO or water at a high enough concentration to generate 
the min controls. The percent inhibition was calculated based 
on the max and min controls on the plate. The definition of a 
hit was a compound that displayed 50% inhibition in the 
primary screen. IC50 value was defined as the concentration 
of inhibitor calculated to inhibit 50% of the assay signal 
based on a serial dilution of compound. Values were calcu-
lated using either a four or three-parameter dose response 
(variable slope) equation in Graphpad Prism or ActivityBase 
(IDBS, Alameda, CA). For the IC50 determinations, serial 
dilutions of compounds were performed in 100% DMSO 
with a two-fold dilution scheme resulting in 10 concentra-
tions of compound starting at a high concentration of 20 μM 
compound in the final assay. For the HTS assay, these com-
pound dilutions were spotted onto plates and the assay per-
formed at 1% DMSO final concentration as described for the 
primary screen.  
RESULTS 
  Bacterial GUS activity can readily be measured using the 
substrate 4-methylumbelliferyl glucuronide (4MUG) [26]. 
Upon hydrolysis of 4MUG by GUS, the fluorescent com-
pound 4-methylumbelliferone (4MU) is generated. We used 
this substrate to detect GUS activity in an end point assay 
that is amenable for high throughput screening for inhibitors 
of GUS. The assay was developed with a final volume of 50 
l using the 384-well plate format to match the intended 
screening format. The general assay set-up included the addi-
tion of diluted GUS enzyme to the well followed by the ad-
dition of 4MUG to initiate the reaction (Fig. 1). The reaction 
was terminated with the addition of a 1 M Na2CO3 solution GUS HTS  Current Chemical Genomics, 2011, Volume 5    15 
and the fluorescence measured in a plate reader. The final 
assay buffer consisted of 50 mM HEPES pH 7.4 and 0.01% 
TX-100. The Km for 4MUG was experimentally determined 
to be 125 μM (data not shown) and therefore this was the 
concentration of 4MUG used in this assay. Stopping of the 
reaction was confirmed by time course studies following 
















Fig. (1). Schematic of the GUS high throughput enzyme assay.  
 
  The activity in the assay was directly proportional to the 
concentration of GUS, up to at least 100 pM enzyme (Fig. 
2). We chose to use 50 pM as the final concentration in the 
assay to provide a robust assay window. This concentration 
of enzyme resulted in a linear time course in this assay for 40 
minutes under final assay conditions in the presence of 1% 
DMSO (Fig. 3). The enzyme titration and time course data 
suggested that the assay conditions should be sensitive to 












Fig. (2). GUS enzyme titration. GUS was titrated into the assay 
under final assay conditions with an incubation time of 30 min in 
the presence of 1% DMSO. Data points represent the average of 
three determinations per concentration and error bars represent 













Fig. (3). GUS assay time course. A time course study was per-
formed under final assay conditions in the presence of 1% DMSO. 
Data points represent the average of three determinations per time 
point and error bars represent standard deviations. Data are repre-
sentative of three independent experiments.  
 
  Since compounds to be screened are dissolved in DMSO, 
the tolerance for DMSO was examined (Fig. 4). The assay 
was shown to be tolerant to DMSO concentrations up to 4%. 
In the final screening assay, the maximal concentration that 
the enzyme is exposed to is 2% DMSO, before the addition 
of substrate, after which the final DMSO was set at 1%. All 













Fig. (4). DMSO tolerance of GUS assay. The indicated concentra-
tions of DMSO were tested in the GUS assay. Data points represent 
the average of three determinations per concentration and error bars 
represent standard deviations. Data are representative of three inde-
pendent experiments.  
 
  The variability of the assay was characterized in a 384-
well plate format. The HTS version of the assay employed a 
work-station level automated liquid handling system using 
the Biomek NX for delivery of compound or DMSO (0.5 l) 
to the plate followed by addition of GUS (30 μl), 4MUG (20 
μl) and Na2CO3  solution (20 μl), in that order, using the 
Multidrop
TM liquid handler (Thermo). To assess single-point 
variability of the assay with full automation, all wells of a 
384-well plate were pre-spotted with 0.5 μl of DMSO (Fig. 
5). The pre-spotted DMSO plates simulated compound plates 
Pipette 0.5 µl of  
compound in DMSO  
Add 30 µl  GUS enzyme 
solution 
Add 20 µl 4MUG solution   
Incubate  30 min 
Add 20 µl sodium 
carbonate solution 
Measure fluorescence 16    Current Chemical Genomics, 2011, Volume 5  Ahmad et al. 
that were to be screened. Two plates for each condition were 
used to determine the maximum (max) signal and minimum 
(min) signal. The %CV of the max and min plates were 2.6 
and 17.5%, respectively. The Z’-factor for the inhibition 
assay window was 0.81. D-Glucaric acid-1,4-lactone has 
been reported to inhibit GUS [31]. The IC50 value for this 
control inhibitor was determined using the HTS protocol, 
including use of automation (Fig. 6). The IC50 values ob-
tained were 21 and 17 μM for two separate determinations. 
Solubility of this control inhibitor limited the use of concen-
trations >100 μM, hence partial IC50 curves were obtained. 
Despite this limitation, these values are in good agreement 
with the published Ki value of 25 μM [31]. The Hill slopes 
were both 1.07, very close to the expected value of 1.0 for 
inhibition of a single enzyme. Thus, reproducible IC50 values 
can be obtained using the automated version of the GUS 
assay. This data indicated that the assay was highly robust 
with minimal variability and amenable for high throughput 












Fig. (5). GUS assay variability assessment. All wells of a 384-
well plate were pre-spotted with 0.5 l of DMSO. Two plates each 
were used to determine the maximum signal () and minimum sig-













Fig. (6). IC50 value determinations using the automated GUS 
assay. Data points represent the average of three determinations per 
concentration and error bars represent standard deviations. Data are 
representative of two independent experiments.  
 
  As part of assay validation, a small collection of 1,120 
compounds purchased from the Prestwick Chemical com-
pany was screened to assess the performance of the assay in 
the presence of diverse compounds using the HTS protocol 
(Fig.  7). The Prestwick collection of compounds was 
screened at 10 μM compound concentration. For this assay, 
the inhibitor cut-off was defined as 50% inhibition based on 
plate controls. Due to solubility limitation of inhibitor, we 
obtained the min controls on screening plates by leaving the 
enzyme out of these wells (buffer alone was added). The 
fluorescence obtained by leaving out the enzyme was the 
same as that of completely inhibited enzyme (data not 
shown). We obtained 40 actives (actives were defined as 
those compounds demonstrating 50% inhibition) from this 
test set screening resulting in a hit rate of 3.6%. The Z’-













Fig. (7). Screen of the Prestwick collection with the GUS assay. 
Each point represents a compound. The percent inhibition values 
were calculated relative to controls on the plates. 
 
  A diverse collection of 11,520 small organic molecules 
were purchased from Asinex Corporation and screened at 10 
M compound concentration for activity in this GUS assay. 
The plate Z’-factors for the screen were all 0.82. A total of 
583 actives ( 50% inhibition) were obtained for an initial 
active rate of 5.1%. We sought to limit follow-up confirma-
tory IC50 determinations to 120 actives, so the active cut-off 
was raised to  89% inhibition to obtain the most potent ac-
tives. Of these 120 compounds tested in IC50 assays, 93 of 
them (77.5%) confirmed with an IC50 of <20 M. The Hill 
slopes generated from such data can be used to triage hits 
since steep slopes, i.e. significantly greater than 1.0, can be 
an indication of compound aggregation which is a non-
specific inhibition mechanism displayed by some com-
pounds [32-33]. Of the 93 confirmed hits, 26 had Hill slopes 
between 0.8 and 1.2. The potencies of these hits ranged from 
50 nM to 4.8 M. The structures and activities of 4 of these 
26 hits have already been published [29]. Here we show the 
structures of 8 more novel GUS inhibitors as representative 
examples of the hits obtained from the screen with IC50 val-
ues ranging from 1.7 to 4.8 M (Table 1). The concentration 
response data used to calculate IC50 values for two com-
pounds are provided as representative curves (Fig. 8). Ex-
amination of the structures from Table 1 indicated that 3 of 
these (compounds 1, 4 and 5) are structurally related to the 
quinolinone thiourea scaffold previously published [29]. 
However, compounds 2, 3 and 6 - 8 are novel and structur-
ally unique inhibitors of GUS.  GUS HTS  Current Chemical Genomics, 2011, Volume 5    17 
Table 1.  Select Confirmed GUS Inhibitors  
Compound  Asinex Identifier 
a  Structure  IC50 (M) 
b 
1  ASN 03367547 
 
1.7 
2  ASN 03795365 
 
1.9 
3  BAS 06980438 
 
1.9 
4  ASN 03272623 
 
2.8 
5  ASN 03776465 
 
3.0 
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(Table 1). Contd….. 
Compound  Asinex Identifier 
a  Structure  IC50 (M) 
b 
7  BAS 02056251 
 
4.0 
8  ASN 03110025 
 
4.8 
aChemical identifier number provided by Asinex Corporation 













Fig. (8). IC50 value determination for two screen hits. Com-
pounds were serially diluted in 100% DMSO then transferred to 
assay plates for the GUS activity assay. Concentration response 
curves are shown for two representative hits from the screen. 
 
DISCUSSION 
  GUS has been used as a reporter enzyme for many years. 
It is also the enzyme whose activity is detected in traditional 
tests for bacterial contamination in water samples. More re-
cently, GUS appears to be responsible for converting the 
inactive CPT-11 metabolite back to active compound in the 
intestine. Active SN-38 in the intestine causes the dose-
limiting diarrhea frequently associated with CPT-11 chemo-
therapy. These data have led to the hypothesis that small 
molecules that inhibit bacterial GUS activity may have po-
tential therapeutic value in preventing CPT-11 mediated di-
arrhea. Limiting this side-effect may allow increased toler-
ance for the therapy and/or allow higher doses resulting in 
better therapeutic outcome. 
  In this report, we have adapted and validated a high 
throughput assay to identify inhibitors of GUS activity and 
used this assay to screen a diverse library of small mole-
cules. The assay signal was shown to increase in a linear 
fashion with enzyme concentration and time. The assay was 
also tolerant up to at least 4% DMSO. As part of the valida-
tion, the control inhibitor D-Glucaric acid-1,4-lactone was 
used to determine IC50 values using the final HTS assay with 
automation. The IC50 values obtained were consistent be-
tween experiments, with the individual values within 12% of 
the mean. Whole 384-well plate variability studies using pre-
spotted DMSO plates and automation were done to assess 
the variability of the assay for detection of inhibitors. The 
results generated Z’-factors of 0.81 for the inhibition assay 
window, indicating a robust assay for detection of hits.  
  As is typical for HTS validation, we screened a small set 
of compounds (the Prestwick collection) using the automated 
assay, to assess the performance of the assay in the presence 
of diverse compounds. This set of four plates resulted in Z’-
factors of 0.8. An active rate of 3.6% was obtained which 
predicted in part, the high 5.1% active rate obtained from the 
Asinex library screen. The higher than expected active rates 
may be due the very low enzyme concentration in the assay 
(50 pM). With no other protein present and only minimal 
detergent present (0.01% Triton X-100), the assay may have 
been more susceptible to compounds that aggregate or have 
reactive impurities present. This explanation is supported by 
the observation that 72% of the confirmed actives had Hill 
slopes that were outside the 0.8 to 1.2 range. It has been re-
ported that compounds that form aggregates in aqueous solu-GUS HTS  Current Chemical Genomics, 2011, Volume 5    19 
tion can non-specifically inhibit purified enzymes, usually 
generating steep Hill slopes (greater than 1.0) in IC50 value 
determinations [32, 33]. The higher active rate obtained in 
the screen compared to the Prestwick set may be, in part, due 
to highly related compounds represented in the Asinex li-
brary as suggested by the number of quinolinone thiourea 
compounds identified as hits. Lowering the compound 
screening concentration, for instance to 1 M, or including 
bovine serum albumin (BSA) in the assay buffer are poten-
tial simple solutions that could reduce this hit rate.  
  From this library screen, at least 26 inhibitors of GUS 
were identified. The hits from Table 1 represent compounds 
that are significantly more potent than the control inhibitor. 
Five of the 8 inhibitors shown here are structurally novel 
inhibitors of GUS. One scaffold that emerged from the hit 
list was the quinolinone thiourea scaffold and highly related 
structures. Four of these compounds were the subject of pub-
lished follow-up studies that demonstrated that these com-
pounds inhibit GUS in living bacteria with IC50 values rang-
ing from 18 to 1,300 nM without affecting cell viability [29]. 
They also did not inhibit mammalian GUS. One of these 
compounds was co-administered to mice receiving CPT-11 
with the result that this compound significantly inhibited 
CPT-11-induced diarrhea. Thus, this GUS assay was suc-
cessful in finding novel inhibitors of GUS activity for further 
study.  
CONCLUSIONS  
  We have developed and validated a fluorescent high 
throughput assay for the discovery of small molecule inhibi-
tors of GUS activity. Whole plate and IC50 variability studies 
confirmed the robustness of this assay for HTS. A chemical 
library was screened resulting in 26 confirmed inhibitors 
with good Hill slopes (0.8 – 1.2) with IC50 values ranging 
from 50 nM to 4.8 M. These compounds may be used as 
starting points for the development of specific small mole-
cule GUS inhibitors as chemical probes. Taken together, the 
GUS assay described herein is amenable for the discovery of 
inhibitors of bacterial GUS. 
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ABBREVIATIONS 
GUS =  -glucuronidase 
DMSO =  dimethyl  sulfoxide 
RFU  =  relative fluorescence units 
GI =  gastrointestinal 
4MUG =  4-methylumbelliferyl  glucuronide 
E. coli  =  Escherichia coli 
IPTG =  isopropyl-1-thio-D-galactopyranoside   
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